Sign in
WithdrawnNo phase

Diagnosis and Treatment of CAD in Severe PAD After Lower Extremity Revascularization

Key facts

Who runs it
VA Office of Research and Development
Where
Aurora, Cleveland, Dallas, Gainesville, Nashville, Pittsburgh, and Seattle, United StatesSee the 7 sites
Trial code
Status
Withdrawn
Started
1 Nov 2024
Ended
1 Nov 2024
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Coronary computed topography (CT) angiography with FFR-CT
Record updated
26 September 2025
Why it stopped
Intent to fund was rescinded

Who can take part

Age
50 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Male or female 50 to 85
  • Severe intermittent claudication with ABI < 0.6 or monophasic waveform if non-compressible and TBI < 0.6
  • Chronic limb threatening ischemia (CLTI) with pain at rest (Rutherford Category 4) with ABI < 0.5 or TBI < 0.6
  • CLTI with minor tissue loss (Rutherford Category 5) with ABI < 0.5 or TBI < 0.6
  • Completed Lower Extremity Revascularization and enrolled within 45 days
  • The patient or legal representative will provide informed written consent
  • The patient has a life expectancy of at least 1 year

Who cannot take part

  • Prior coronary artery bypass graft (CABG) revascularization surgery
  • Prior percutaneous coronary intervention (PCI) with angioplasty or stenting
  • Pregnancy, Human Immunodeficiency Virus, or organ transplant recipients
  • Uncompensated congestive heart failure (NYHA class IV)
  • Myocardial infarction or stroke within the past 90 days
  • Current malignancy or malignancy within the last two years unless the treating oncologic physician provides prognosis of an anticipated 2- year survival (i.e., adequately treated non-melanoma skin cancer or adequately treated prostate cancer without metastatic disease)
  • Any condition the review panel determines would make the patient unsuitable for participation in the study
  • Congestive heart failure with Ejection Fraction < 30%
  • Severe Chronic renal disease (Glomerular Filtration Rate, GFR < 30) or on hemodialysis
  • Major tissue loss of the ischemic limb (Rutherford Category 6)
  • Presence of a pacemaker
  • Elevated liver function tests more than twice the upper limit of normal

Where in United States

  • Rocky Mountain Regional VA Medical Center, Aurora, COAurora, United States
  • Louis Stokes VA Medical Center, Cleveland, OHCleveland, United States
  • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TXDallas, United States
  • North Florida/South Georgia Veterans Health System, Gainesville, FLGainesville, United States
  • Tennessee Valley Healthcare System Nashville Campus, Nashville, TNNashville, United States
  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PAPittsburgh, United States
  • VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, United States

About the trial

What the trial wants to find out

Peripheral artery disease, lack or blood flow to the legs, has a high prevalence in the Veteran population. In patients with severe peripheral artery disease that requires an endovascular or surgical intervention for lower leg revascularization, the long-term mortality of approximately 50% is worse that most cancers. The goal of this study is to develop a management strategy to improve cardiovascular outcomes in this high-risk peripheral artery disease population after lower extremity revascularization.

The 2 groups in the trial

  • Investigational Treatment StrategyTreatment being tested

    This arm will have a coronary CTA with FFR-CT with selective coronary artery revascularization plus optimal medical therapy after lower extremity revascularization

    Treatment: Coronary computed topography (CT) angiography with FFR-CT

  • StandardNo study treatment, for comparison

    This arm will have optimal medical therapy after lower extremity revascularization

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Diagnosis and Treatment of Coronary Artery Disease in Severe Peripheral Artery Disease After Lower Extremity Revascularization
Record updated
26 September 2025